Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor <scp>TM5614</scp> combined with a tyrosine kinase inhibitor-Reference-Cited by-同舟云学术

Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor

Published:2022-09-23 Issue:4 Volume:12 Page:4250-4258
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Takahashi Naoto¹^ORCID,Kameoka Yoshihiro¹,Onizuka Makoto²,Onishi Yasushi³,Takahashi Fumiaki⁴,Dan Takashi⁵,Miyata Toshio³,Ando Kiyoshi²,Harigae Hideo³

Affiliation:

1. Akita University School of Medicine Akita Japan

2. Tokai University School of Medicine Isehara Japan

3. Tohoku University, Sendai Japan

4. Iwate Medical University Morioka Japan

5. Renascience Inc. Tokyo Japan

Funder

Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5292

Reference32 articles.

1. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

2. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

3. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

4. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN)

5. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial;British Journal of Dermatology;2024-06-04

2. Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer;Journal of Thoracic Disease;2024-05

3. Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors;Expert Opinion on Pharmacotherapy;2024-01-22

4. A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19;Scientific Reports;2024-01-02

5. A PAI‐1 antagonist ameliorates hypophosphatemia in the Hyp vitamin D‐resistant rickets model mouse;FEBS Open Bio;2023-12-25